



## EDITORIALS

**103 Establishing cost-effectiveness of atypical neuroleptics**

G. Robert and P. Kennedy

**105 Maternal stress or anxiety in pregnancy and emotional development of the child**

V. Glover

**107 Long-term cannabis use and mental health**

W. Hall and N. Solowij

## REVIEW ARTICLE

**109 Pharmacokinetic interactions involving clozapine**

D. Taylor

## EVIDENCE-BASED PSYCHIATRY

**113 Lithium: evidence reconsidered**

J. Moncrieff

**120 Lithium: balancing risks and benefits**

J. Cookson

## PAPERS

**125 Cost-effectiveness of clozapine. A UK clinic-based study**

K. J. Aitchison and R. W. Kerwin

**131 Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care**

C. Scott, M. J. Tacchi, R. Jones and J. Scott

**135 Controlled trial of exposure and response prevention in obsessive-compulsive disorder**

M. Lindsay, R. Crino and G. Andrews

**140 Incidence of schizophrenia in Nottingham. A comparison of two cohorts, 1978-80 and 1992-94**

J. Brewin, R. Cantwell, T. Dalkin, R. Fox, I. Medley, C. Glazebrook, R. Kwiecinski and G. Harrison

**145 Increased rate of psychosis among African-Caribbeans in Britain is not due to an excess of pregnancy and birth complications**

G. Hutchinson, N. Takei, D. Bhugra, T. A. Fahy, C. Gilvarry, R. Mallett, P. Moran, J. Leff and R. M. Murray

**148 Incidence and risk factors for severe tardive dyskinesia in older patients**

M. P. Caligiuri, J. P. Lacro, E. Rockwell, L. A. McAdams and D. V. Jeste

**154 Executive (frontal) dysfunction and negative symptoms in schizophrenia: apparent gender differences in 'static' v. 'progressive' profiles**

P. J. Scully, G. Coakley, A. Kinsella and J. L. Waddington

**159 Service provision for people with schizophrenia: I. Clinical and economic perspective**

F. H. Lang, J. F. Forbes, G. D. Murray and E. C. Johnstone

**165 Service provision for people with schizophrenia: II. Role of the general practitioner**

F. H. Lang, E. C. Johnstone and G. D. Murray

**169 Integration between primary and secondary services in the care of the severely mentally ill: patients' and general practitioners' views**

J. Bindman, S. Johnson, S. Wright, G. Szmukler, P. Bebbington, E. Kuipers and G. Thornicroft

**175 "Anybody's child": severe disorders of mother-to-infant bonding**

R. C. Kumar

**182 Plasma noradrenaline response to electroconvulsive therapy in depressive illness**

C. B. Kelly and S. J. Cooper

## COLUMNS

**187 Correspondence**

**190 One hundred years ago**

**190 Corrigendum**

**191 Reading about**

**194 Book reviews**

**199 Contents of *The American Journal of Psychiatry***

# George doesn't know what SSRI means ...

... He just knows his doctor made a logical choice

AUG 14 1997  
PROPERTY OF  
MEDICAL LIBRARY  
ST. BARNABAS HOSPITAL  
183rd St. & 3rd Ave.  
Brook, N. Y. 10457



“... **SSRIs** deserve consideration as first-line therapy for depression in older patients”



**Cipramil**▼  
citalopram  
*your partner in depression*

**Presentation:** 'Cipramil' tablets. PL 0458/0058, each containing 20mg of citalopram as the hydrobromide. 28 (OP) 20mg tablets £21.28. **Indications:** Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. **Dosage: Adults:** 20mg a day. Depending upon individual patient response, this may be increased in 20mg increments to a maximum of 60mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. **Elderly:** 20mg a day increasing to a maximum of 40mg dependent upon individual patient response. **Children:** Not recommended. Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-indications:** Combined use of 5-HT agonists. Hypersensitivity

operating machinery. History of mania. Caution in patients at risk of cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. **Overdose:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd., Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. 'Cipramil' is a



# THE BRITISH JOURNAL OF PSYCHIATRY

AUGUST 1997 VOL. 171

AUG 14 1997

**EDITOR** Greg Wilkinson LIVERPOOL

**DEPUTY EDITOR**  
Alan Kerr  
NEWCASTLE UPON TYNE

**ASSOCIATE EDITORS**  
Sidney Crown  
LONDON

Julian Leff  
LONDON

Sir Martin Roth  
CAMBRIDGE

Sir Michael Rutter  
LONDON

Peter Tyrer  
LONDON

**EDITORIAL ADVISERS**

Tony Johnson  
CAMBRIDGE

Kathleen Jones  
YORK

Martin Knapp  
LONDON

Herschel Prins  
LEICESTER

Sir John Wood  
SHEFFIELD

**ASSISTANT EDITORS**

Mohammed Abou-Saleh  
AL AIN

Louis Appleby  
MANCHESTER

German Berrios  
CAMBRIDGE

Alistair Burns  
MANCHESTER

Patricia Casey  
DUBLIN

John Cookson  
LONDON

David Cottrell  
LEEDS

Nigel Eastman  
LONDON

Tom Fahy  
LONDON

Anne Farmer  
CARDIFF

Michael Farrell  
LONDON

Nicol Ferrier  
NEWCASTLE UPON TYNE

William Fraser  
CARDIFF

Richard Harrington  
MANCHESTER

Sheila Hollins  
LONDON

Jeremy Holmes  
BARNSTAPLE

Alexander Kellam  
CARDIFF

Peter Kennedy  
YORK

Michael King  
LONDON

Alan Lee  
NOTTINGHAM

Glyn Lewis  
CARDIFF

Shôn Lewis  
MANCHESTER

Robin McCreadie  
DUMFRIES

Ian McKeith  
NEWCASTLE UPON TYNE

Roy McClelland  
BELFAST

David Owens  
LEEDS

Ian Pullen  
MELROSE

Rosalind Ramsay  
LONDON

Henry Rollin  
LONDON

Jan Scott  
NEWCASTLE UPON TYNE

Mike Shooter  
CARDIFF

Andrew Sims  
LEEDS

Jeanette Smith  
BRISTOL

George Stein  
LONDON

David Tait  
PERTH

**CORRESPONDING EDITORS**

Sidney Bloch  
AUSTRALIA

Patrice Boyer  
FRANCE

J. M. Caldas de Almeida  
PORTUGAL

Andrew Cheng  
TAIWAN

Andrei Cristian  
ROMANIA

E. L. Edelstein  
ISRAEL

Václav Filip  
CZECH REPUBLIC

Heinz Katschnig  
AUSTRIA

Kenneth Kendler  
USA

Toshi Kitamura  
JAPAN

Arthur Kleinman  
USA

F. Lieh Mak  
HONG KONG

Jair Mari  
BRAZIL

Harold Merskey  
CANADA

Paul Mullen  
AUSTRALIA

Ahmed Okasha  
EGYPT

Volodymyr Poltavetz  
UKRAINE

Michele Tansella  
ITALY

Toma Tomov  
BULGARIA

John Tsiantis  
GREECE

J. L. Vázquez-Barquero  
SPAIN

Richard Warner  
USA

**STATISTICAL ADVISER**

Pak Sham  
LONDON

**STAFF**

PUBLICATIONS MANAGER  
Dave Jago

SCIENTIFIC EDITOR

Andrew Morris

ASSISTANT SCIENTIFIC EDITOR

Lucretia King

EDITORIAL ASSISTANTS

Zofia Ashmore

Julia Ashford

Rachel Gold

MARKETING ASSISTANT

Dominic Bentham

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists (a registered charity, registration number 228636). The *BJP* publishes original work in all fields of psychiatry. Manuscripts for publication should be sent to the Editor, *British Journal of Psychiatry*, 17 Belgrave Square, London SW1X 8PG. Queries, letters to the Editor and book reviews may also be sent electronically to [zashmore@rcpsych.ac.uk](mailto:zashmore@rcpsych.ac.uk).

Full instructions to authors are given at the beginning of the January and July issues, and on the Web Site below.

Information about the College's publications is available on the World Wide Web at <http://www.demon.co.uk/rcpsych>.

**Subscriptions**

Non-members of the College should contact the Publications Subscription Department, Royal Society of Medicine Press Limited, PO Box 9002, London W1A 0ZA (tel. 0171 290 2928; fax 0171 290 2929). Annual subscription rates for 1997 (12 issues post free) are as follows:

	INSTITUTIONS	INDIVIDUALS
Europe (& UK)	£165	£145
US	\$320	\$236
Elsewhere	£196	£155

Full airmail is £36/  
US\$64 extra.

Single copies of the  
journal are £14, \$25  
(post free).

Queries from non-members about missing or faulty copies should be addressed within six months to the same address; similar queries from College members should be addressed to the Registration Subscription Department, The Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG.

Payment should be made out to the British Journal of Psychiatry.

**Back issues**

Back issues published before 1996 may be purchased from William Dawson & Sons Ltd, Cannon House, Folkestone, Kent (tel. 01303 850 101).

**Advertising**

Correspondence and copy should be addressed to Peter T. Mell, Advertising Manager, PTM Publishers Ltd, 282 High Street, Sutton, Surrey SMI 1PQ (tel. 0181 642 0162; fax 0181 643 2275).

**US Mailing Information**

The *British Journal of Psychiatry* is published monthly by the Royal College of Psychiatrists. Subscription price is \$320. Second class postage paid at Rathway, NJ. Postmaster send address corrections to the British Journal of Psychiatry, c/o Mercury Airfreight International Ltd Inc., 2323 Randolph Avenue, Avenel, New Jersey 07001.

The paper used in this publication meets the minimum requirements of the American National Standard for Information Sciences - Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

Typeset by Dobbie Typesetting Ltd, Tavistock.

Printed by Henry Ling Ltd, The Dorset Press, 23 High East Street, Dorchester, Dorset DT1 1HD.

**Past Editors**

Eliot Slater	1961-72	John L. Crammer	1978-83
Edward H. Hare	1973-77	Hugh L. Freeman	1984-93

Founded by J. C. Bucknill in 1853 as the *Asylum Journal* and known as the *Journal of Mental Science* from 1858 to 1963.

©1997 The Royal College of Psychiatrists. Unless so stated, material in the *British Journal of Psychiatry* does not necessarily reflect the views of the Editor or the Royal College of Psychiatrists. The publishers are not responsible for any error of omission or fact.

## **CIDI-Auto 2.1**

Computerised version of the Composite International Diagnostic Interview v2.1 for epidemiological and clinical research, and for clinical support for ICD-10 and DSM-IV diagnoses.

Program, manual and training video  
US\$ 500, Stg 320.

World Health Organization Collaborating  
Centre: 299 Forbes Street, Darlinghurst,  
NSW, Australia 2010.

Fax: +61 2 9332 4316  
E-mail: [judyo@crufad.unsw.edu.au](mailto:judyo@crufad.unsw.edu.au)  
[http://www.unsw.edu.au/clients/crufad/  
home.htm](http://www.unsw.edu.au/clients/crufad/home.htm)

## **CALL FOR PAPERS**

### **FOURTH ANNUAL CONFERENCE**

on

### **GAY, LESBIAN AND BISEXUAL ISSUES IN PSYCHIATRY**

**27-28 February 1998  
Sydney, Australia**

For information please contact:

Dr Michael S. Armstrong  
Level 4, Beanbah Chambers  
235 Macquarie Street  
Sydney NSW 2000  
Australia

Tel: +61 2 9231 3230  
Fax: +61 2 9231 3117  
Email: [msa@ozemail.com.au](mailto:msa@ozemail.com.au)  
[www.ozemail.com.au/~msa](http://www.ozemail.com.au/~msa)

## **DIRECT MEDICAL APPOINTMENTS**

The Consultants Choice

**LOCUM positions available NOW**

Long or Short Term

**Top Rates**

All areas of the UK

**Choice of Quality Consultant Posts**

Documentation/Visa arranged

Permanent and Substantive Positions

**CALL NOW FOR A  
PROFESSIONAL SERVICE**

Tel: +44 (0)1792 472525

Fax: +44 (0)1792 472535

E-mail: [medical.appointments@cyberstop.net](mailto:medical.appointments@cyberstop.net)

## **BROADMOOR HOSPITAL AUTHORITY**

**Working with difference**

**The Practitioner  
The Patient  
The Service**

A unique course to focus on service provision for the mentally ill black patient. This modular, day release course commencing in September for 12 weeks will explore transcultural concepts, institutional power and racism, clinical practice issues and the challenge of developing a practical model of equitable service delivery.

For more information please contact:

Linda Lowe  
Training & Education Centre  
Broadmoor Hospital Authority  
Crowthorne  
Berkshire  
RG45 7EG

Tel: 01344 754405

# PRESCRIPTION FOR DEPRESSION




Illustration © Janet Atkinson/SIS Paris

## Tender loving care and

# SEROXAT

PAROXETINE

'Seroxat' helps get depressed patients back to normal, liberating them from everyday stresses and anxiety.

For all those depressed patients who need a helping hand to face life again, make 'Seroxat' your first-choice prescription for depression.

Rebuilding the lives  
of anxious depressed patients

### Prescribing information

**Presentation** 'Seroxat' Tablets, PL 10592/0001-2, each containing either 20 or 30 mg paroxetine as the hydrochloride. 30 (OP) 20 mg tablets, £20.77; 30 (OP) 30 mg tablets, £31.16. 'Seroxat' Liquid, PL 10592/0092, containing 20 mg paroxetine as the hydrochloride per 10 ml. 150 ml (OP), £20.77. **Indications** Treatment of symptoms of depressive illness of all types including depression accompanied by anxiety. Treatment of symptoms of obsessive compulsive disorder (OCD). Treatment of symptoms and prevention of relapse of panic disorder with or without agoraphobia. **Dosage Adults:** *Depression:* 20 mg a day. Review response within two to three weeks and if necessary increase dose in 10 mg increments to a maximum of 50 mg according to response. *Obsessive compulsive disorder:* 40 mg a day. Patients should be given 20 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 60 mg a day. *Panic disorder:* 40 mg a day. Patients should be given 10 mg a day initially and the dose increased weekly in 10 mg increments. Some patients may benefit from a maximum dose of 50 mg a day. Give orally once a day in the morning with food. The tablets should not be chewed. Continue treatment for a sufficient period, which may be several months for depression or longer for OCD and panic disorder. As with many psychoactive medications abrupt discontinuation should be avoided – see **Adverse reactions.** *Elderly:* Dosing should commence at the adult starting dose and may be increased in weekly 10 mg increments up to a maximum of 40 mg a day according to response. *Children:* Not recommended. *Severe renal impairment (creatinine clearance <30 ml/min) or severe hepatic impairment:* 20 mg a day. Restrict incremental dosage if required to lower end of range. **Contra-indication** Hypersensitivity to paroxetine. **Precautions** History of mania. Cardiac conditions: caution. Caution in patients with epilepsy; stop treatment if seizures develop. Driving and operating machinery. **Drug interactions** Do not use with or within two weeks after MAO inhibitors; leave a two-week gap before starting MAO inhibitor treatment. Possibility of interaction with tryptophan. Great caution with warfarin and other oral anticoagulants. Use lower doses if given with drug metabolising enzyme inhibitors; adjust dosage if necessary with drug metabolising enzyme inducers. Alcohol is not advised. Use lithium with caution and monitor lithium levels. Increased adverse effects with phenytoin; similar possibility with other anticonvulsants. **Pregnancy and lactation** Use only if potential benefit outweighs possible risk. **Adverse reactions** In controlled trials most commonly nausea, somnolence, sweating, tremor, asthenia, dry mouth, insomnia, sexual dysfunction (including impotence and ejaculation disorders), dizziness, constipation and decreased appetite. Also spontaneous reports of dizziness, vomiting, diarrhoea, restlessness, hallucinations, hypomania, rash including urticaria with pruritus or angioedema, and symptoms suggestive of postural hypotension. Extrapyrimal reactions reported infrequently; usually reversible abnormalities of liver function tests and hyponatraemia described rarely. Symptoms including dizziness, sensory disturbance, anxiety, sleep disturbances, agitation, tremor, nausea, sweating and confusion have been reported following abrupt discontinuation of 'Seroxat'. It is recommended that when antidepressant treatment is no longer required, gradual discontinuation by dose-tapering or alternate day dosing be considered. **Overdosage** Margin of safety from available data is wide. Symptoms include nausea, vomiting, tremor, dilated pupils, dry mouth, irritability, sweating and somnolence. No specific antidote. General treatment as for overdosage with any antidepressant. Early use of activated charcoal suggested. **Legal category** POM. 3.3.97

**SB** **SmithKline Beecham**  
Pharmaceuticals

Welwyn Garden City, Hertfordshire AL7 1EY 'Seroxat' is a registered trade mark.  
© 1997 SmithKline Beecham Pharmaceuticals



Books Beyond Words  
Series from Gaskell

# You're on Trial

Sheila Hollins, Glynis Murphy  
and Isabel Clare,  
illustrated by Beth Webb

The pictures and text in this book are intended to show the likely events when someone with learning disabilities or mental health needs comes into contact with the criminal justice system. The intended readership is people with learning disabilities or difficulties or mental health needs. The 'story' is told in pictures without any words although there is a text at the back of the book which may be useful too. You can make any story you like from the book as it will fit any crime and any verdict.

This book is a joint publication between the Royal College of Psychiatrists and St. George's Hospital Medical School. The authors all work with people with learning disabilities.

● £10.00 ● 72pp. ● 1996 ● ISBN 1 901242 00 5

Also available in this series:  
*You're under Arrest*, price £10.00.

Gaskell books are available from the Publications  
Department, Royal College of Psychiatrists,  
17 Belgrave Square, London SW1X 8PG  
(Tel. +44(0)171 235 2351, extension 146).

The latest information on College publications is  
available on the INTERNET at:  
<http://www.demon.co.uk/rcpsych/>

# An advance in the treatment of depression



DIRECTLY ACTS ON BOTH  
SEROTONIN AND NORADRENALINE<sup>1</sup>



HIGH RESPONSE RATES<sup>2,3</sup>



REDUCES AGITATION<sup>4</sup> AND IMPROVES  
SLEEP PATTERNS<sup>5</sup> AFTER 1 WEEK



LOW POTENTIAL FOR DRUG  
INTERACTIONS<sup>\*\*6-9</sup>

\*\*HEALTHY VOLUNTEER STUDIES

# EFEXOR<sup>\*</sup>

VENLAFAXINE 37.5mg b.d.


SEROTONIN NORADRENALINE REUPTAKE INHIBITOR

**PRESCRIBING INFORMATION:** PRESENTATION: Tablets containing 37.5mg, 50mg or 75mg venlafaxine (as hydrochloride). USE: Treatment of depressive illness. DOSAGE: Usually 75mg/day (37.5mg bd) with food, increasing to 150mg/day (75mg bd) if necessary. In more severely depressed patients, 150mg/day (75mg bd) increasing every 2 or 3 days in up to 75mg/day increments to a maximum of 375mg/day, then reducing to usual dose consistent with patient response. Discontinue gradually. Elderly: use normal adult dose. Children: contraindicated. Doses should be reduced by 50% for moderate renal or moderate hepatic impairment. CONTRA-INDICATIONS: Pregnancy, lactation, concomitant use with MAOIs, hypersensitivity to venlafaxine or other components, patients aged below 18 years. PRECAUTIONS: Use with caution in patients with myocardial infarction, unstable heart disease, of seizure). Patients should not drive or operate machinery if their ability

management. Monitor blood pressure with doses > 200mg/day. Advise patients to notify their doctor should an allergy develop or if they become or intend to become pregnant. Use with caution in patients taking other CNS-active drugs or in the elderly or hepatically-impaired patients taking cimetidine. Patients with a history of drug abuse should be monitored carefully. Not recommended in severe renal or severe hepatic impairment. INTERACTIONS: MAOIs: do not use Efexor in combination with MAOIs or within 14 days of stopping MAOI treatment. Allow 7 days after stopping Efexor before starting a MAOI. SIDE-EFFECTS: Nausea, headache, insomnia, somnolence, dry mouth, dizziness, constipation, asthenia, sweating, nervousness, anorexia, dyspepsia, abdominal pain, anxiety, impotence, abnormality of accommodation, vasodilation, paraesthesia, abnormal ejaculation/orgasm, chills, hypertension, palpitation, weight gain, agitation, decreased libido, rise

BASIC NHS PRICE: 37.5mg tablet (PL 0011/0199) – Calendar pack of 56 tablets: £23.97, 50mg tablet (PL 0011/0200) – Blister pack of 42 tablets: £23.97, 75mg tablet (PL 0011/0201) – Calendar pack of 56 tablets: £39.97. LEGAL CATEGORY: POM. Further information is available upon request. PRODUCT LICENCE HOLDER: Wyeth Laboratories (John Wyeth & Brother Limited), Taplow, Maidenhead, Berkshire, SL6 0PH. Space photography provided courtesy of National Aeronautics and Space Administration (NASA). References: 1. Muth EA *et al.* *Biochem Pharmacol* 1986; 35(24): 4493-4497. (EX00007). 2. Dierick M *et al.* *Prog Neuropsychopharmacol Biol Psychiat* 1996; 20: 57-71. 3. Clerc GE *et al.* *Int Clin Psychopharmacol* 1994; 9(3): 139-143. (EX00101). 4. Entsuah R *et al.* *Human Psychopharmacol* 1995; 10: 195-200. 5. Data on file, 635. 6. Troy SM *et al.* *J Clin Pharmacol* 1995; 35: 410-419. 7. Data on file, 20276. 8. Parker V *et al.* *J Clin Pharmacol* 1991; 3(9): 867 (Abstract 110). (EX00023). 9. Troy S *et al.* *Clin Neuropharm* 1992; **Wyeth**

THE CONSTANT CURRENT  
SERIES 5B E.C.T. APPARATUS



ECTONUS Constant Current Series 5B

Supplementing the Constant Current Series 5A ECT Apparatus

ECTONUS and ECTONUSTIM models available from the manufacturers with over 48 years of experience in the design of E.C.T. equipment.

**ECTRON LTD**

KNAP CLOSE LETCHWORTH HERTS ENGLAND SG6 1AQ  
Telephone 01462 682124 Fax 01462 481463

**NB**  
MEDICAL  
EDUCATION

LONDON

MRCPsych PART I

Intensive exam-oriented weekend courses

- Covering: Theory for *new syllabus*  
Technique & tactics  
Over 2000 relevant MCQs  
Practice MCQ exams
- Dates: London: 6, 7 & 13, 14 September 1997  
The Secretary  
NB Medical Education  
PO Box 767  
Oxford  
OX1 2YU
- Full details: 01865 790514
- HM 67 (27) approval for study leave

**BPP**  
MEDICAL  
EDUCATION

Intensive weekend courses  
BPP training centre, London

MRCPsychiatry Parts I & II  
Written and Clinical skills courses

Part I Written 13-14 September 1997  
Part II Written 13-14 September 1997  
Part II Clinical 1-2 November 1997

BPP Courses are  
Stimulating, entertaining and successful.

Telephone or Fax 0181-959-7562  
33 Flower Lane, Mill Hill, London NW7

# Mum has Alzheimer's



- **The first selective treatment** for the symptoms of mild or moderate dementia in Alzheimer's disease licensed in the UK<sup>1,2</sup>
- **Improvements** in cognitive symptoms and global function<sup>3-5</sup>
- **Well tolerated**<sup>6</sup>
- **Simple** once daily dosage.

but she knew I was calling today

**new** ● **once daily**  
**Aricept**<sup>®</sup>  
donepezil hydrochloride



**A first step in Alzheimer's**

#### BRIEF PRESCRIBING INFORMATION


ARICEPT<sup>®</sup> (donepezil hydrochloride)

Please refer to the SmPC before prescribing ARICEPT 5mg or ARICEPT 10mg. **Indication:** Symptomatic treatment of mild or moderate dementia in Alzheimer's disease. **Dose and administration:** **Adults/elderly:** 5mg once daily which may be increased to 10mg once daily after at least one month. No dose adjustment necessary for patients with renal or mild-moderate hepatic impairment. **Children:** Not recommended. **Contra-indications:** Hypersensitivity to donepezil, piperidine derivatives or any excipients used in ARICEPT. **Pregnancy and lactation:** Use only if benefit outweighs risk. Excretion into breast milk unknown. **Precautions:** Potential for interaction with cholinergic agonists and anticholinergics particularly exaggeration of

of vagotonic effect on the heart which may be particularly important with "sick sinus syndrome" and supraventricular conduction conditions. Careful monitoring of patients who are at risk of ulcer disease including those receiving NSAIDs. Cholinomimetics may cause bladder outflow obstruction. Seizures occur in Alzheimer's disease and cholinomimetics have the potential to cause seizures. Prescribe with care in patients suffering asthma and obstructive pulmonary disease. **Side effects:** Most commonly diarrhoea, muscle cramps, fatigue, nausea, vomiting, insomnia and dizziness. Minor increases in muscle creatine kinase but no notable laboratory abnormalities reported. **Presentation and basic NHS cost:** Blister packed in strips of 14. ARICEPT 5mg; white, film coated tablets marked 5 and Aricept, packs of 28 £68.32.

Aricept, packs of 28 £95.76. **Marketing authorisation numbers:** ARICEPT 5mg; PL 10555/0006 ARICEPT 10mg; PL 10555/0007. **Marketing authorisation holder:** Eisai Europe Ltd. **Further information from/Marketed by:** Eisai Ltd, Hammersmith International Centre, 3 Shortlands, London, W6 8EE and Pfizer Ltd, Sandwich, Kent, CT13 9NJ. **Legal category:** POM. **Date of preparation:** May 1997. **References:** 1. Kelly CA et al. Br Med J 1997; 314: 693-694. 2. Rogers SL et al. In: Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhauser; 1991: 314-320. 3. Data on file (A301). 4. Data on file (A302) and Rogers SL et al. Neurology 1996; 46: A217. 5. Rogers SL et al. Dementia 1996; 7: 293-303. 6. Data on file, Integrated Summary of Safety.

# AKATHISIA TREMOR DYSTONIA RIGIDITY




#### Serdolect:<sup>®</sup> Abbreviated Prescribing Information

**Presentation:** Tablets of 4mg, 12mg, 16mg or 20mg sertindole. **Indications:** Treatment of schizophrenia. Not for urgent relief of symptoms in acutely disturbed patients. **Dosage and administration:** Tablets should be taken orally once daily without regard for food. *Adults.* All patients should be started on 4mg/day. The dose should be increased by 4mg increments after 4-5 days on each dose to the optimum daily maintenance dose range of 12-20mg. The dose may be increased to a maximum of 24mg. Retitration is necessary if dosing is suspended for more than one week. *Children.* Not recommended. *Mild to moderate hepatic impairment.* Slower titration and lower maintenance dose. *Elderly.* Slower titration and lower maintenance doses may be required. **Contraindications:** Concomitant use with Class I antiarrhythmics (e.g., quinidine, procainamide, flecainide, propafenone) or Class III antiarrhythmics (e.g., sotalolol, dofetilide) or combined use of drugs known to prolong QT interval. Clinically significant cardiac disease or

be initiated if required but a potassium-sparing agent must be used. Combined use of quinidine or systemic ketoconazole or itraconazole. Severe hepatic impairment. Hypersensitivity to Serdolect. **Pregnancy and lactation:** Safety during human pregnancy and lactation has not been established and Serdolect should not be used during pregnancy. Nursing mothers should not breastfeed if they are taking Serdolect. **Precautions:** Serdolect is not sedative, however, patients should be advised not to drive or operate machinery until their individual susceptibility is known. History of diabetes, seizures, Parkinson's disease. Symptoms of orthostatic hypotension may occur and blood pressure should be monitored during initial dose titration and in early maintenance phase. In common with other antipsychotic drugs, Serdolect lengthens the QT interval in some patients (<1.7% of patients). Electrolyte imbalance or combined use with other drugs that may affect electrolyte balance should be avoided.

# CUT IT OUT


## A new window of opportunity



is opening in the treatment of schizophrenia, with the promise of substantial improvements to the quality of patients' lives.

Serdolect® is a novel limbic-selective anti-psychotic.

Pre-clinical studies have shown that it inhibits the number of spontaneously active dopamine neurones in the mesolimbic ventral tegmental area without affecting dopamine neurones in the substantia nigra. Furthermore, it has been found to be more selective than certain other atypical drugs.<sup>1</sup> This indicates that Serdolect® may have a lower potential for producing extra-pyramidal side-effects across the therapeutic range.



## Serdolect® opens the window of opportunity for your patients

- Effective against positive and negative symptoms<sup>2,3</sup>
- Placebo-level EPS at all doses tested<sup>2,3</sup>
- Sedation at placebo level<sup>4</sup>
- No clinically significant changes in haematological parameters<sup>4</sup>
- Mean serum prolactin levels maintained within normal limits<sup>4</sup>
- Once daily dosage
- One price for all routine maintenance doses

Thankfully, such a profile not only extends your choice, it also opens the window of opportunity for your patients.

**Serdolect®** ▼

**sertindole**

*Separates efficacy from EPS*

monitoring on treatment. Serdolect should not be initiated or should be discontinued if the QTc2 interval exceeds 520 msec. Hypokalaemia and hypomagnesaemia should be corrected and maintained within normal limits during treatment. If signs and symptoms of tardive dyskinesia appear, consider dose reduction or discontinuation. **Drug interactions:** (Also see contra-indications). Combined use of agents known to inhibit hepatic isoenzymes may necessitate lower maintenance doses. Combined use of agents known to induce hepatic isoenzymes may necessitate maintenance doses toward the upper dose range. **Adverse events:** Most commonly (>1 % of patients): nasal congestion, decreased ejaculatory volume, dizziness, dry mouth, postural hypotension, weight gain, peripheral oedema, dyspnoea, paraesthesia and prolonged QT interval. Incidence of EPS adverse events similar to placebo. **Overdosage:** Symptoms have included somnolence, slurred speech, tachycardia, hypotension and transient prolongation of QT interval. Treatment is supportive and symptomatic. Epiacohine and

dopamine should not be used (may exacerbate hypotension). Cardiovascular monitoring recommended. Administration of activated charcoal and laxative should be considered. **Package quantities and basic NHS price:** 4mg tablets, £36.63 for 30 tablet pack. 12mg tablets, £102.55 for 28 tablet calendar pack. 16mg tablets, £102.55 for 28 tablet calendar pack. 20mg tablets, £102.55 for 28 tablet calendar pack. **Legal category:** POM. **Product Licence numbers:** 4mg: 13761/0001. 12mg: 13761/0003. 16mg: 13761/0004. 20mg: 13761/0005. **Date of last review:** November 1996. Further information is available on request from Lundbeck Limited, Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. Serdolect® is a registered trademark of H. Lundbeck A/S. **References:** 1. Arnt J *et al.* Poster presented at the 34th ACNP Meeting, December 1995, Puerto Rico. 2. Zborowski J *et al.* Poster presented at 148th APA Meeting, May 1995, Miami, Florida. 3. Daniel DG *et al.* J. Psychiatry. In Press. 4. Data on file. H. Lundbeck A/S.

# When you next patient, ask h of lipstick



Edronax®  
ABBREVIATED PRESCRIBING INFORMATION

**Presentation:** Tablets containing 4mg reboxetine. **Indications:** Use in the treatment of depressive illness. The remission of the acute phase of the depressive illness is associated with an improvement in the patient's quality of life in terms of social adaptation. The positive effect is also seen on accessory symptoms such as anxiety, insomnia, and decreased activity level. **Posology and method of administration:** Adults 4mg b.i.d.

**children. Contra-indications:** Hypersensitivity to the compound. **Special warnings and precautions for use:** In elderly patients a dose reduction is recommended. In renal impairment or patients with hepatic insufficiency a dose adjustment may be required. Close supervision is required for subjects with a history of convulsive disorders and must be discontinued if the patient develops seizures. Avoid concomitant use with MAO inhibitors. Close supervision of bipolar patients is recommended. Close supervision should be applied in patients with current evidence of urinary retention and glaucoma. At

reboxetine with other drugs known to lower blood pressure. Experience of long-term treatment of elderly patients is, at present, limited. Lowering of mean potassium levels in the elderly was found, but levels never dropped below normal limits. **Interactions with other medicaments and other forms of interaction:** Concomitant use e.g.: potassium losing diuretics, blood pressure lowering drugs. Concomitant use with other antidepressants not evaluated. Possible interaction with other drugs which also bind to  $\alpha_1$  acid glycoprotein should be considered. **Pregnancy and lactation. Administration**

# see a depressed er which shade she wears.

**S**elf pride is just part of how well a depressed patient re-adapts socially, and social interaction is an extremely valuable measure of successful treatment.

Edronax is a new selective NorAdrenaline Re-uptake Inhibitor (NARI). It not only lifts depressed mood<sup>1,2</sup>, but also significantly improves social interaction<sup>3</sup>.

These improvements in social function have been trial-proven by using the innovative, SASS (Social Adaptation Self-evaluation Scale) questionnaire<sup>3</sup>.

Edronax improves mood at least as effectively as fluoxetine<sup>4</sup>. Additionally, when compared to fluoxetine,

Edronax shows a significantly better outcome in terms of social functioning<sup>3</sup>.

Edronax helps restore patients' appreciation of friends, family, work, hobbies and improves their self-perception.

Prescribe 4mg b.d. then make your usual assessments to see the Edronax difference. The SASS questionnaire, which patients can complete in their own time, may also help.

For free copies of the SASS questionnaire, please telephone 0181 957 5156.

**Edronax**  
REBOXETINE

**A NEW SELECTIVE NARI. LIFTS DEPRESSION. HELPS RESTORE SOCIAL INTERACTION.**


exposure to the drug. **Effects on ability to drive and use machines:** Caution patients about operating machinery and driving. **Undesirable effects:** Adverse events occurring most frequently are: dry mouth, constipation, insomnia, paraesthesia, increased sweating, tachycardia, hypotension, dizziness, vertigo, urinary hesitancy/retention, impotence, the latter mainly observed in patients treated with doses higher than 8mg/day. In the elderly population, newly observed rhythm disorders (mainly tachycardia) and conduction disorders were apparent on ECG in a minority of cases. **Overdose:** Monitor cardiac

**Category:** POM **Marketing Authorisation Holder:** Pharmacia & Upjohn Limited. **Marketing Authorisation Number:** PL 0032/0216. **Date of Preparation:** June 1997. **References:** 1. Berzowski H, Van Moffaert M, Gagiano CA. *European Neuropsychopharmacology*. 1997; 7 (Suppl 1): S37-S47. 2. Data on file, Pharmacia & Upjohn Ltd. 3. Dubini A, Bosc M, Poin V. *European Neuropsychopharmacology*. 1997; 7 (Suppl 1): S48-S55. 4. Data on file, Pharmacia & Upjohn Ltd. Further information is available from Pharmacia & Upjohn Limited, Davy Avenue, Knowlhill, Milton Keynes,



# HE'S SURVIVED 1 WORLD WAR, 2 REDUNDANCIES AND 9 GOVERNMENTS

BUT HE CAN'T FIGHT DEPRESSION ALONE




*Treats older patients with the respect they deserve*

**Molipaxin**  
trazodone HCl

Molipaxin (trazodone hydrochloride) 50 and 100mg capsules, Molipaxin tablets 150mg, Molipaxin CR tablets 150mg, Molipaxin Liquid (50mg/5ml). **Indications:** Relief of symptoms in all types of depression including depression accompanied by anxiety. Symptoms likely to respond in the first week include depressed mood, insomnia, anxiety, somatic symptoms and hypochondriasis. **Dosage and Administration:** Starting dose of Molipaxin is 150mg daily taken in divided doses after food or as a single dose at retiring. This may be increased to 300mg/day the major portion of which is preferably taken at retiring. In hospitalised patients, dosage may be further increased to 600mg/day in divided doses. **Dosage in the elderly and frail:** Starting dose of 100mg/day in divided doses or as a single night-time dose. This may be increased, under supervision, according to efficacy and tolerance. Doses above 300mg/day are unlikely to be required. Cessation of Molipaxin should be gradual. **Children:** Not recommended. **Contra-indications:** Known sensitivity to trazodone. **Precautions:** Avoid during first trimester of pregnancy and in nursing mothers. Warn against risks of handling machinery and driving. May enhance muscle relaxants, some antihypertensive agents, sedatives or antidepressants and alcohol, acute effects of clonidine may be reduced. Avoid concurrent therapy with MAOIs and do not give Molipaxin within 2 weeks of stopping MAOIs or give MAOIs within 1 week of stopping Molipaxin. Use with care in patients with epilepsy, severe hepatic, cardiac or renal disease. Patients receiving long-term therapy with any antidepressant should be kept under regular surveillance. **Side effects:** Molipaxin is a sedative antidepressant. Any dizziness or drowsiness usually disappears on continued dosage. Anticholinergic-like symptoms occur, but the incidence is similar to placebo. Blood dyscrasias, including agranulocytosis, thrombocytopenia and anaemia, have been reported on rare occasions. Adverse effects on hepatic function, including jaundice and hepatocellular damage, sometimes severe, have been rarely reported. Should such effects occur, Molipaxin should be discontinued immediately. As with other drugs with alpha-adrenergic activity, Molipaxin has very rarely been associated with priapism. This may be treated with an intracavernosal injection of alpha-adrenergic agents such as adrenaline or metaraminol. However, there are reports of trazodone-induced priapism which have on occasion required surgical intervention or led to permanent sexual dysfunction. Priapism should be dealt with as an urological emergency and Molipaxin therapy should be discontinued immediately. Other side effects include isolated cases of oedema and postural hypotension. **Overdosage:** No specific antidote is available. Give supportive and symptomatic treatment. **Legal Category:** POM. **Presentations, product licence numbers and basic NHS prices:** Molipaxin 50mg, 84 capsules; 0109/0045; £17.31. Molipaxin 100mg, 56 capsules; 0109/0046; £20.38. Molipaxin 150mg, 28 tablets; 0109/0133; £11.62. Molipaxin CR 150mg, 28 tablets; 0109/0214; £11.62. Molipaxin Liquid 50mg/5ml, 150ml bottle; 0109/0117; £7.74. **Product Licence Holder:** Roussel Laboratories Ltd, Broadwater Park, Denham, Uxbridge, Middlesex UB9 5HP. **Distributor:** Marion Merrell Ltd, Broadwater Park, Denham, Uxbridge, Middlesex UB9 5HP. Further product information is available from Hoechst Marion Roussel Ltd at the above address. Hoechst Marion Roussel is a member of the Hoechst Group. © Molipaxin is a registered trademark.

Date of issue: Dec 1996

## New Brief Pulse ECT with *Computer-Assisted* Easy Seizure Monitoring



### Somatics Thymatron™ DGx

- Automatically monitors your choice of EEG-EEG, EEG-ECG, or EEG-EMG and determines EEG and motor seizure lengths.
- Computer-measured seizure quality, including postictal EEG suppression, seizure energy index.
- Up to 8 seconds stimulus duration; pulsewidth as short as 0.5 ms.
- Single dial sets stimulus charge by age; high-dose option available.
- FlexDial™ adjusts pulsewidth and frequency without altering dose.

Distributed in U.S.A., Canada, and Mexico by:



**SOMATICS, INC.**  
910 Sherwood Drive # 17  
Lake Bluff IL 60044 U.S.A.

**Fax: (847) 234-6763**  
**Tel: (847) 234-6761**

### Selected Distributors

<b>Distributed in the U.K. by:</b> DANTEC Electronics, Ltd. Garonor Way Royal Portbury Bristol BS20 9XE TEL (44) 1275-375333 FAX (44) 1275-375336	<b>Distributed in New Zealand by:</b> WATSON VICTOR, Ltd. 4 Adelaide Rd. Wellington, New Zealand TEL (64) 4-385-7699 FAX (64) 4-384-4651
<b>Distributed in India by:</b> DIAGNO.SYS New Delhi TEL (91) 11-644-0546 FAX (91) 11-622-9229	<b>Distributed in South Africa by:</b> DELTA SURGICAL Craighall TEL (27) 11-792-6120 FAX (27) 11-792-6926
<b>Distributed in Australia by:</b> MEECO Holdings Pty. Ltd. 10 Seville St. North Parramatta NSW 2151 Australia TEL (61) 2630-7755 FAX (61) 2630-7365	<b>Distributed in Scandinavia by:</b> MEDICAL EQUIPMENT APS Bygaden 51A P.O. Box 23 DK-4040 Jyllinge, Denmark TEL (45) 4-6788746 FAX (45) 4-6788748
<b>Distributed in Pakistan by:</b> IQBAL & CO. Islamabad TEL (92) 51-291078 FAX (92) 51-281623	<b>Distributed in Israel by:</b> BEPEX, LTD. 16, Galgalei Haplada St. Herzliya 46722 TEL (972) 9-959586211 FAX (972) 9-9547244

## N O R T H E A S T E R N H E A L T H C A R E N E T W O R K

WORKING TOGETHER TO IMPROVE  
HEALTH SERVICES IN THE NORTH EAST



The North Eastern Health Care Network consists of  
Austin & Repatriation Medical Centre, Bundoora Extended Care Centre,  
Mercy Hospital for Women, Preston & Northcote Community Hospital,  
Royal Talbot Rehabilitation Centre, and The Northern Hospital – from 1998.

Melbourne, Australia

### PROFESSOR/DIRECTOR

#### National Centre for War-related Post Traumatic Stress Disorder

Melbourne, Victoria, the intellectual and cultural capital of Australia, is home to The University of Melbourne, recognised internationally for excellence in teaching and research.

The National Centre for War-related Post Traumatic Stress Disorder (PTSD) was established in May 1995 as an initiative of the Department of Veterans' Affairs (DVA) in conjunction with the University, and it maintains a close working relationship with the DVA and its committees.

Located at the Austin and Repatriation Medical Centre, Heidelberg, Victoria, the person will direct the activities of the National Centre for War-related PTSD. The principal role of the National Centre is to work with DVA to facilitate the development and delivery of quality services for PTSD and co-morbidities, to eligible veterans and their families. The National Centre sets guidelines, provides treatment protocols, and provides accreditation to service providers. At present, there are nine clinics delivering programs throughout Australia. Other key roles are to collaborate with the Australian Defence Force to develop early intervention and treatment strategies with respect to PTSD and to educate clinicians and others about the condition. The position will include opportunities for teaching and postgraduate student supervision as well as research.

You will be a registered medical practitioner specialising in psychiatry. You will be a clinician with research experience in the field of PTSD or a closely related area. You will have administrative experience in dealing with government authorities and other organisations, and a good understanding of systems of health care and differing models of service delivery in the psychiatric area. Demonstrated clinical expertise in the treatment of traumatic stress syndromes is essential.

The remuneration package is negotiable but will be based on that available to a Senior Staff Specialist with a major teaching hospital. The right to private practice will be negotiated. The position is offered for 5 years.

Position description available by phoning Human Resources Directorate (613) 9496 2171.

**Enquiries:** Professor G. Burrows, Director, Psychiatry & Psychology, Clinical Service Unit (613) 9496 5665.

**Position No.:** A161. **Closing Date:** Friday 29 August 1997.

Applications, including a curriculum vitae and the names of 3 referees to the:

**Employment Consultant, Human Resources Directorate,  
Repatriation Campus, Banksia Street, West Heidelberg,  
Victoria, Australia 3081.**



**Veterans'  
Affairs**

**WE WON'T  
PROMISE  
THE WORLD**



# OLANZAPINE

**ABBREVIATED PRESCRIBING INFORMATION: Presentation:** Coated tablets containing 5mg, 7.5mg or 10mg of olanzapine. The tablets also contain lactose. **Uses:** Schizophrenia, both as initial therapy and for maintenance of response. **Further Information:** In studies of patients with schizophrenia and associated depressive symptoms, mood score improved significantly more with olanzapine than with haloperidol. Olanzapine was associated with significantly

greater improvements in both negative and positive schizophrenic symptoms than placebo or comparator in most studies. **Dosage and Administration:** 10mg/day orally, as a single dose without regard to meals. Dosage may subsequently be adjusted within the range of 5-20mg daily. An increase to a dose greater than the routine therapeutic dose of 10mg/day is recommended only after clinical assessment. **Children:** Not recommended under 18 years of age. **The elderly:** A lower starting dose (5mg/day) is not routinely indicated but should be considered when clinical factors warrant. **Hepatic and/or renal impairment:** A lower starting dose (5mg) may be considered. When more than one factor is present which might result in slower metabolism (female gender, elderly age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation should be conservative in such patients. **Contra-indications:** Known hypersensitivity to any ingredient of the product.

**Precautions:** Caution in patients with prostatic hypertrophy, or paralytic ileus and related conditions. Caution in patients with elevated ALT and/or AST, signs and symptoms of hepatic impairment pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic drugs. As with other neuroleptic drugs, caution in patients with low leucocyte and/or neutrophil counts for any reason; a history of drug-induced bone marrow depression/toxicity, bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypersensitivity conditions or with myeloproliferative disease. Thirty-two patients with clozapine-related neutropenia or agranulocytosis histories received olanzapine without decreases in baseline neutrophil counts. Although, in clinical trials, there were no reported cases of NMS in patients receiving olanzapine, if such an event occurs, or if there is unexplained high

 **PSYCHIATRY**  
Improving lives, restoring hope





Schizophrenia treatments can't promise to put patients' lives back the way they were. But the right choice of medication may help them find a place in their community.

Zyprexa demonstrated improvement in the negative as well as the positive symptoms of schizophrenia (in four out of five controlled trials in patients presenting with both positive and negative symptoms).<sup>1-3</sup>

With a simple once-daily dosage and no requirement for routine blood or ECG monitoring,<sup>4</sup> Zyprexa may offer a step towards community re-integration.

**Antipsychotic Efficacy for First-line Use**

**ZYPREXA**  
**Olanzapine**



**Making Community Re-integration the Goal**

Caution in patients who have a history of seizures or have conditions associated with seizures. If signs or symptoms of tardive dyskinesia appear a dose reduction or drug discontinuation should be considered. Caution when taken in combination with other centrally acting drugs and alcohol. Olanzapine may antagonise the effects of direct and indirect dopamine agonists. Postural hypotension was infrequently observed in the elderly. However, blood pressure should be measured periodically in patients over 65 years, as with other antipsychotics. As with other antipsychotics, caution when prescribed with drugs known to increase QTc interval, especially in the elderly. In clinical trials, olanzapine was not associated with a persistent increase in absolute QT intervals. **Interactions:** Metabolism may be induced by concomitant smoking or carbamazepine therapy. **Pregnancy and Lactation:** Olanzapine had no teratogenic effects in animals. Because human experience is limited, olanzapine

risk to the foetus. Olanzapine was excreted in the milk of treated rats but it is not known if it is excreted in human milk. Patients should be advised not to breast feed an infant if they are taking olanzapine. **Driving, etc:** Because olanzapine may cause somnolence, patients should be cautioned about operating hazardous machinery, including motor vehicles. **Undesirable Effects:** The only frequent (>10%) undesirable effects associated with the use of olanzapine in clinical trials were somnolence and weight gain. Occasional undesirable effects included dizziness, increased appetite, peripheral oedema, orthostatic hypotension, and mild, transient anticholinergic effects, including constipation and dry mouth. Transient, asymptomatic elevations of hepatic transaminases, ALT, AST have been seen occasionally. Olanzapine-treated patients had a lower incidence of Parkinsonism, akathisia and dystonia in trials compared with titrated doses of haloperidol. Photosensitivity reaction or high creatinine

elevated, but associated clinical manifestations were rare. Asymptomatic haematological variations were occasionally seen in trials. *For further information see summary of product characteristics.* **Legal Category:** POM **Marketing Authorisation Numbers:** EU/1/96/022/004 EU/1/96/022/005 EU/1/96/022/009 EU/1/96/022/010. **Basic NHS Cost:** £52.73 per pack of 2 x 5mg tablets. £105.47 per pack of 28 x 10mg tablets. £158.20 per pack of 56 x 7.5mg tablets. £210.93 per pack of 56 x 10mg tablets. **Date of Preparation:** August 1996. **Full Prescribing Information is Available From:** Lilly Industries Limited, Dextra Court, Chapel Hill, Basingstoke, Hampshire RG2 5SY. Telephone: Basingstoke (01256) 315000. 'ZYPREXA' is a Lilly trademark. **References:** 1. Data on file, Lilly Industries. 2. Data on file, Lilly Industries. 3. Zyprexa Summary of Product Characteristics, Section 5.1: Pharmacodynamic Properties. 4. Zyprexa Summary of Product



Books Beyond Words  
Series from Gaskell

# You're under Arrest

Sheila Hollins, Isabel Clare  
and Glynis Murphy,  
illustrated by Beth Webb

The pictures and text in this book are intended to reflect the procedures used by the police when an adult with learning difficulties or mental health needs is under arrest. The intended readership is people with learning disabilities or difficulties or mental health needs. The 'story' is told in pictures without any words although there is a text at the back of the book which may be useful too. You can make any story you like from the book as it will fit any crime.

This book is a joint publication between the Royal College of Psychiatrists and St. George's Hospital Medical School. The authors all work with people with learning disabilities.

● £10.00 ● 72pp. ● 1996 ● ISBN 1 901242 01 3

Also available in this series:  
*You're on Trial*, price £10.00.

Gaskell books are available from the Publications  
Department, Royal College of Psychiatrists,  
17 Belgrave Square, London SW1X 8PG  
(Tel. +44(0)171 235 2351, extension 146).  
The latest information on College publications is  
available on the INTERNET at:  
<http://www.demon.co.uk/rcpsych/>

## RISPERDAL™ ABBREVIATED PRESCRIBING INFORMATION

Please refer to Summary of Product Characteristics before prescribing Risperdal (risperidone). USES The treatment of acute and chronic schizophrenia, and other psychotic conditions, in which positive and/or negative symptoms are prominent. Risperdal also alleviates affective symptoms associated with schizophrenia. DOSAGE Where medically appropriate, gradual discontinuation of previous antipsychotic treatment while Risperdal therapy is initiated is recommended. Where medically appropriate, when switching patients from depot antipsychotics, consider initiating Risperdal therapy in place of the next scheduled injection. The need for continuing existing antiparkinson medication should be re-evaluated periodically. Adults: Risperdal may be given once or twice daily. All patients, whether acute or chronic, should start with 2 mg/day. This should be increased to 4 mg/day on the second day and 6 mg/day on the third day. However, some patients such as first-episode psychotic patients may benefit from a slower rate of titration. From then on the dosage can be maintained unchanged, or further individualised if needed. The usual effective dosage is 4 to 8 mg/day although in some patients an optimal response may be obtained at lower doses. Doses above 10 mg/day may increase the risk of extrapyramidal symptoms and should only be used if the benefit is considered to outweigh the risk. Doses above 16 mg/day should not be used. Elderly, renal and liver disease: A starting dose of 0.5 mg bd is recommended. This can be individually adjusted with 0.5 mg bd increments to 1 to 2 mg bd. Risperdal is well tolerated by the elderly. Use with caution in patients with renal and liver disease. Not recommended in children aged less than 15 years. CONTRAINDICATIONS, WARNINGS, ETC. Contraindications: Known hypersensitivity to Risperdal. Precautions: Orthostatic hypotension can occur (alpha-blocking effect). Use with caution in patients with known cardiovascular disease. Consider dose reduction if hypotension occurs. For further sedation, give an additional drug (such as a benzodiazepine) rather than increasing the dose of Risperdal. Drugs with dopamine antagonistic properties have been associated with tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotic drugs should be considered. Caution should be exercised when treating patients with Parkinson's disease or epilepsy. Patients should be advised of the potential for weight gain. Risperdal may interfere with activities requiring mental alertness. Patients should be advised not to drive or operate machinery until their individual susceptibility is known. Pregnancy and lactation: Use during pregnancy only if the benefits outweigh the risks. Women receiving Risperdal should not breast feed. Interactions: Use with caution in combination with other centrally acting drugs. Risperdal may antagonise the effect of levodopa and other dopamine agonists. On initiation of carbamazepine or other hepatic enzyme-inducing drugs, the dosage of Risperdal should be re-evaluated and increased if necessary. On discontinuation of such drugs, the dosage of Risperdal should be re-evaluated and decreased if necessary. Side effects: Risperdal is generally well tolerated and in many instances it has been difficult to differentiate adverse events from symptoms of the underlying disease. Common adverse events include: insomnia, agitation, anxiety, headache. Less common adverse events include: somnolence, fatigue, dizziness, impaired concentration, constipation, dyspepsia, nausea/vomiting, abdominal pain, blurred vision, priapism, erectile dysfunction, ejaculatory dysfunction, orgasmic dysfunction, urinary incontinence, rhinitis, rash and other allergic reactions. The incidence and severity of extrapyramidal symptoms are significantly less than with haloperidol. However, the following may occur: tremor, rigidity, hypersalivation, bradykinesia, akathisia, acute dystonia. If acute, these symptoms are usually mild and reversible upon dose reduction and/or administration of antiparkinson medication. Rare cases of Neuroleptic Malignant Syndrome have been reported. In such an event, all antipsychotic drugs should be discontinued. Occasionally, orthostatic dizziness, hypotension (including orthostatic), tachycardia (including reflex) and hypertension have been observed. An increase in plasma prolactin concentration can occur which may be associated with galactorrhoea, gynaecomastia and disturbances of the menstrual cycle. Oedema and increased hepatic enzyme levels have been observed. A mild fall in neutrophil and/or thrombocyte count has been reported. Rare cases of water intoxication with hyponatraemia, tardive dyskinesia, body temperature dysregulation and seizures have been reported. Overdosage: Reported signs and symptoms include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. A prolonged QT interval was reported in a patient with concomitant hypokalaemia who had ingested 360mg. Establish and maintain a clear airway, and ensure adequate oxygenation and ventilation. Gastric lavage and activated charcoal plus a laxative should be considered. Commence cardiovascular monitoring immediately, including continuous electrocardiographic monitoring to detect possible arrhythmias. There is no specific antidote, so institute appropriate supportive measures. Treat hypotension and circulatory collapse with appropriate measures. In case of severe extrapyramidal symptoms, give anticholinergic medication. Continue close medical supervision and monitoring until the patient recovers. PHARMACEUTICAL PRECAUTIONS Tablets: Store below 30°C. Liquid: Store between 15°C and 30°C and protect from freezing. LEGAL CATEGORY POM. PRESENTATIONS, PACK SIZES, PRODUCT LICENCE NUMBERS & BASIC NHS COSTS White, oblong tablets containing 1 mg risperidone in packs of 20. PL 0242/0186 £13.45. Pale orange, oblong tablets containing 2 mg risperidone in packs of 60. PL 0242/0187 £79.56. Yellow, oblong tablets containing 3 mg risperidone in packs of 60. PL 0242/0188 £117.00. Green, oblong tablets containing 4 mg risperidone in packs of 60. PL 0242/0189 £154.44. Starter packs containing 6 Risperdal 1 mg tablets are also available £4.15. Clear, colourless solution containing 1 mg risperidone per ml in bottles containing 100 ml. PL 0242/0199 £65.00. FURTHER INFORMATION IS AVAILABLE FROM THE PRODUCT LICENCE HOLDER: Janssen-Cilag Ltd, Saunderton, High Wycombe, Buckinghamshire HP14 4HJ.

Date of preparation: April 1997

© Janssen-Cilag Ltd  
™ trademark

801116



# Patient with schizophrenia exercises *self* esteem by going downhill



The SDA effect of Risperdal can mean a huge difference to the lives of patients with schizophrenia.

Because SDA is the action of Serotonin and Dopamine Antagonism in a single drug. In positive and negative symptoms. In first episode and acute presentations, and in chronic patients. Risperdal continues to provide this SDA effect to give high efficacy, with low levels of extrapyramidal side-effects. to more and more patients.

Helping them keep out of hospitals while enhancing their appreciation of, and participation in, community and family life.

The word is on the street.



**Risperdal™**  
RISPERIDONE

A routine route out

Now accepting nominations

## THE 1997 LILLY SCHIZOPHRENIA REINTEGRATION AWARDS

Eli Lilly and Company is sponsoring its second annual awards program to recognise outstanding achievements in helping patients with schizophrenia and related disorders reintegrate into their communities.

Inaugurated in Europe in 1996, the awards programme, with the support of the World Psychiatric Association, covers Europe, Latin America and Asia-Pacific. Any individual or group involved in some aspect of the reintegration process is eligible to be nominated in one of these categories:

- \*Clinical Medicine
- \*Nursing
- \*Social Work
- \*Journalism

Winners will be selected from each region and the awards will be presented to them at this year's WPA meetings scheduled for: Beijing, China, 7-10 October; Santiago, Chile, 22-25 October; Jerusalem, Israel, 16-21 November.

The three service awards consist of a \$5,000 contribution to the winner's charity or institution, a certificate, a commemorative memento and travel expenses to the WPA meeting for the awards presentation.

Deadlines are:

15 August, Asia-Pacific; 15 September, Latin America; 30 September, Europe.

For further details and an entry form contact:

Lilly Awards Secretariat  
Weber & Associates

P.O. Box 80  
Thame OX9 3GX  
England

Tel: +44 (1844) 216716  
Fax: +44 (1844) 260706



## Consultant Psychiatrist Positions in New Zealand

We have positions available for consultant psychiatrists in a major service provider in Auckland, New Zealand. Opportunities are available in most sub-specialities. Posts may be taken up between now and early 1998.

The service provides acute in-patient, day care and extensive community support programmes to a population of approximately 300,000. Acute in-patient services are provided from a brand new facility.

To be considered for these positions you will have experience in, and commitment to, contemporary models of therapy and a commitment to the growth of this exciting service. An interest in cross cultural psychiatry will be an advantage.

New Zealand's Medical Registration regime means that only those applicants with recognised Commonwealth or American College senior post-graduate qualifications are likely to be considered.

Assistance with Immigration and registration processes will be given and relocation expenses will be negotiated. Appropriately qualified applicants may be eligible for Permanent Residence of New Zealand.

Please submit your full curriculum vitae to:

New Zealand Medical Staffing Ltd, PO Box 74-385, Market Road,  
Auckland, New Zealand

Fax: +64-9-630 9622, email: [info@healthlinknz.co.nz](mailto:info@healthlinknz.co.nz)

New Zealand  
MEDICAL STAFFING



UNIVERSITY OF  
**TEESSIDE**  
SCHOOL OF HEALTH

The First Cleveland Mental Health Conference  
"RISK AND RESOURCES IN COMMUNITY CARE"

University of Teesside

Friday 5 September 1997, 9.30-3.30

### Speakers

Jayne Zito, of the Zito Trust  
Mr David Keating, The Law Society  
Miss Jane Budworth, MIND  
Mr Geoffrey Harrison, Eversheds Solicitors  
Professor Ian Hindmarch, University of Surrey  
Professor David Benton, University of Northumbria  
Mr Harper Brown, Tees Health Purchasing Commission  
Dr Roy Curtis, The Royal College of Psychiatrists Research Unit

Managing risk alongside the advance of mental health services brings pressures on clinicians, managers and purchasers. This conference aims to bring together nationally eminent speakers involved in mental health care to present and debate important and up to date issues before a multi-disciplinary audience.

To book a place at this conference, please forward a £20 registration fee, payable to The Centre for Health and Medical Research, University of Teesside, to: Dr Stephen D. Martin, Centre for Health and Medical Research, School of Health, University of Teesside, Middlesbrough TS1 3BA, Tel: 01642 384124, Fax: 01642 384143, E-mail: [Linda.Ratcliffe@tees.ac.uk](mailto:Linda.Ratcliffe@tees.ac.uk)

### Call for Posters

If you would like to submit an abstract for a poster presentation, please send a 250 word summary to the above address before Friday 8 August 1997. There is no registration fee for successful poster applicants.

# Now we've turned our thoughts to psychiatry.

Zeneca have an ongoing programme of initiatives aimed at supporting those involved in caring for the seriously mentally ill.

- A series of annual regional workshops - Management Issues in Schizophrenia.
  - The Zeneca/BAP Annual Poster Award.
- The Zeneca/UKPPG Travel Award.
  - RCP/NSF schizophrenia information leaflets.
- Annual English CPNA/Zeneca conferences.
- Research fora, to investigate controversies in community care, advances in pharmaceutical therapies and managing treatment-resistant patients.
- A wallchart outlining the ICD-10 schizophrenia diagnoses.

## NEW INITIATIVES

- A pocketbook guide to schizophrenia.
- UKPPG psychiatric medication helpline number available from October
  - NSF New Carer Support Pack\*, funded by Zeneca.
- Sponsors of the Bethlem & Maudsley NHS Trust 750th Anniversary celebrations

For more information on these events, please call Zeneca Pharma on 0800 200 123.



Granted To ICI Pharmaceuticals



# ZENECA

THINKING AHEAD IN PSYCHIATRY

# CLOZARIL®

clozapine

**CLOZARIL ABBREVIATED PRESCRIBING INFORMATION.** The use of CLOZARIL is restricted to patients registered with the CLOZARIL Patient Monitoring Service. **Indication:** Treatment-resistant schizophrenia (patients non-responsive to, or intolerant of, conventional neuroleptics). **Presentations** 25 mg and 100 mg clozapine tablets. **Dosage and Administration** Initiation of CLOZARIL treatment must be in hospital in-patients and is restricted to those patients with a normal white blood cell count and differential count. Initially, 12.5 mg once or twice on first day, followed by one or two 25 mg tablets on second day. Increase slowly, initially by daily increments of 25 to 50 mg, followed by increments of 50 to 100 mg to reach a therapeutic dose within the range of 200 to 450 mg daily. The total daily dose should be divided and a larger portion of the dose may be given at night. Once control is achieved a maintenance dose of 150 to 300 mg daily may suffice. At daily doses not exceeding 200mg, a single administration in the evening may be appropriate. Exceptionally, doses up to 900 mg daily may be used. Patients with a history of epilepsy should be closely monitored during CLOZARIL therapy since dose-related convulsions have been reported. Therefore, patients with a history of seizures, as well as those suffering from cardiovascular, renal or hepatic disorders, together with the elderly need lower doses (12.5 mg given once on the first day) and more gradual titration. **Contra-Indications** Hypersensitivity to clozapine. History of drug-induced neutropenia/agranulocytosis, myeloproliferative disorders, uncontrolled epilepsy, alcoholic and toxic psychoses, drug intoxication, comatose conditions, circulatory collapse and/or CNS depression of any cause and severe hepatic, renal or cardiac failure. **Warning** CLOZARIL can cause agranulocytosis. A fatality rate of up to 1 in 300 has been estimated when CLOZARIL was used prior to recognition of this risk. Since that time strict haematological monitoring of patients has been demonstrated to be effective in markedly reducing the risk of fatality. Because of the risk associated with CLOZARIL therapy its use is therefore limited to treatment-resistant schizophrenic patients:- 1. who have normal leucocyte findings (white blood cell count and differential blood count), and 2. in whom regular leucocyte counts can be performed weekly during the first 18 weeks and at least every two weeks thereafter for the first year of therapy. After one years treatment monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue as long as treatment continues. Patients must be under specialist supervision and CLOZARIL supply is restricted to hospital and community pharmacies registered with the CLOZARIL Patient Monitoring Service. Prescribing physicians must register themselves, their patients and a nominated pharmacist with the CLOZARIL Patient Monitoring Service. This service provides for the required leucocyte counts as well as a drug supply audit so that CLOZARIL treatment is promptly withdrawn from any patient who develops abnormal leucocyte findings. Each time CLOZARIL is prescribed, patients should be reminded to contact the treating physician immediately if any kind of infection begins to develop. Particular attention should be paid to flu-like complaints or other symptoms which might suggest infection, such as fever or sore throat. **Precautions** CLOZARIL can cause agranulocytosis. Perform pre-treatment white blood cell count and differential count to ensure only patients with normal findings receive CLOZARIL. Monitor white blood cell count weekly for the first 18 weeks and at least two-weekly for the first year of therapy. After one years treatment, monitoring may be changed to four weekly intervals in patients with stable neutrophil counts. Monitoring must continue as long as treatment continues. If the white blood count falls below  $3.0 \times 10^9/l$  and/or the absolute neutrophil count drops below  $1.5 \times 10^9/l$ , withdraw CLOZARIL immediately and monitor the patient closely, paying particular attention to symptoms suggestive of infection. Re-evaluate any patient developing an infection, or with a routine white blood count between  $3.0$  and  $3.5 \times 10^9/l$  and/or a neutrophil count between  $1.5$  and  $2.0 \times 10^9/l$ , with a view to discontinuing CLOZARIL. Any further fall in white blood/neutrophil count below  $1.0 \times 10^9/l$  and/or  $0.5 \times 10^9/l$  respectively, after drug withdrawal requires immediate specialised care. Where protective isolation and administration of GM-CSF or G-CSF may be indicated. Colony stimulating factor therapy should be discontinued when the neutrophil count returns above  $1.0 \times 10^9/l$ . CLOZARIL lowers the seizure threshold. Orthostatic hypotension can occur therefore close medical supervision is required during initial dose titration.

Monitor hepatic function in liver disease. Use with care in prostatic enlargement, narrow-angle glaucoma and paralytic ileus. Patients affected by the sedative action of CLOZARIL should not drive or operate machinery. CLOZARIL should be administered with caution to patients who participate in activities requiring complete mental alertness. Patients with fever should be carefully evaluated to rule out the possibility of an underlying infection or the development of agranulocytosis. Do not give CLOZARIL with other drugs with a substantial potential to depress bone marrow function. CLOZARIL may enhance the effects of alcohol, MAO inhibitors, CNS depressants and drugs with anticholinergic, hypotensive or respiratory depressant effects. Caution is advised when CLOZARIL therapy is initiated in patients who are receiving (or have recently received) a benzodiazepine or any other psychotropic drug as these patients may have an increased risk of circulatory collapse, which, on rare occasions, can be profound and may lead to cardiac and/or respiratory arrest. Caution is advised with concomitant administration of therapeutic agents which are highly bound to plasma proteins. Clozapine binds to and is partially metabolised by the isoenzyme cytochrome P450 2D6. Caution is advised with drugs which possess affinity for the same isoenzyme. Concomitant cimetidine and high dose CLOZARIL was associated with increased plasma clozapine levels and the occurrence of adverse effects. Discontinuation of concomitant carbamazepine resulted in increased clozapine levels. Phenytoin decreases clozapine levels resulting in reduced effectiveness of CLOZARIL. No clinically relevant interactions noted with antidepressants, phenothiazines and type Ic antiarrhythmics observed, to date. Isolated reports of fluvoxamine increasing clozapine plasma levels by 5-10 fold. Concomitant use of lithium or other CNS-active agents may increase the risk of neuroleptic malignant syndrome. The hypertensive effect of adrenaline and its derivatives may be reversed. Do not use in pregnant or nursing women. Use adequate contraceptive measures in women of child bearing potential. **Side-Effects** Neutropenia leading to agranulocytosis (See Warning and Precautions). Rare reports of leucocytosis including eosinophilia. Isolated cases of leukaemia and thrombocytopenia have been reported but there is no evidence to suggest a causal relationship with the drug. Most commonly fatigue, drowsiness, sedation. Dizziness or headache may also occur. CLOZARIL lowers the seizure threshold and may cause EEG changes and delirium. Myoclonic jerks or convulsions may be precipitated in individuals who have epileptogenic potential but no previous history of epilepsy. Rarely it may cause confusion, restlessness, agitation and delirium. Extrapyramidal symptoms are limited mainly to tremor, akathisia and rigidity. Neuroleptic malignant syndrome has been reported. Transient autonomic effects eg dry mouth, disturbances of accommodation and disturbances in sweating and temperature regulation. Hypersalivation. Tachycardia and postural hypotension, with or without syncope, and less commonly hypertension may occur. In rare cases profound circulatory collapse has occurred. ECG changes, arrhythmias, pericarditis and myocarditis (with or without eosinophilia) have been reported, some of which have been fatal. Isolated cases of respiratory depression or arrest, with or without circulatory collapse. GI disturbances, increases in hepatic enzymes. In rare cases, cholestasis has been reported and very rarely ileus may occur. Rarely aspiration may occur in patients presenting with dysphagia or as a consequence of acute overdose. Both urinary incontinence and retention and priapism have been reported. Benign hyperthermia may occur and isolated reports of skin reactions have been received. Rarely, hyperglycaemia has been reported. Rarely increases in CPK values have occurred. With prolonged treatment considerable weight gain has been observed. Sudden unexplained deaths have been reported in patients receiving CLOZARIL. **Package Quantities and Price** Community pharmacies only. 28 x 25mg tablets: £12.52 (Basic NHS) 28 x 100mg tablets: £50.05 (Basic NHS). Hospital pharmacies only. 84 x 25 mg tablets: £37.54 (Basic NHS). 84 x 100 mg tablets: £150.15 (Basic NHS). Supply of CLOZARIL is restricted to hospital and community pharmacies registered with the CLOZARIL Patient Monitoring Service. **Product Licence Numbers** 25 mg tablets: PL 0101/0228. 100 mg tablets: PL 0101/0229. **Legal Category** POM. CLOZARIL is a registered Trade Mark. **Date of preparation** January 1996. Full prescribing information, including Product Data Sheet is available from SANDOZ PHARMACEUTICALS. Frimley Business Park, Frimley, Camberley, Surrey, GU16 5SG.



After two neuroleptics had failed  
Clozaril got to work...



...so did Steve

How long should you wait?

**CLOZARIL**<sup>®</sup>  
clozapine

Proven efficacy in treatment-resistant schizophrenia

## WORLD MENTAL HEALTH CARE FROM GASKELL



Available from good bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146)

### **Mental Disorders in China**

English Version Editors:  
John E. Cooper & Norman Sartorius

This is the first available account in English of the results of the 1982 Chinese Epidemiological Survey of Mental Disorder. It is the only nationwide Chinese study to involve modern methods of case assessment and is uniquely large and interesting, involving 51982 persons. The use of the Present State Examination in the survey allows the symptomatic basis of diagnoses, such as neurasthenia, to be examined. The results indicate that the prevalence of schizophrenia is similar to that found recently in other countries, but that the prevalence of other mental disorders may be lower.  
£15.00, 128pp., 1996, ISBN 0 902241931

### **Mental Health Care in China**

**State Policies, Professional Services and Family Responsibilities**

by Veronica Pearson

This book traces the development of psychiatric services in China. Historical, policy and legal frameworks are constructed to provide a context in which psychiatric services may be better understood. The experience of both staff and patients in one particular hospital is examined in detail. The book raises questions about the similarities in the experience of psychiatric illness across significantly different cultures.  
£12.50, 218pp., 1995, ISBN 0 902241 74 5

GASKELL ACADEMIC SERIES

## **The Analysis of Hysteria**

Second Edition

Understanding Conversion and Dissociation

By Harold Merskey

This book is a substantial update and enlargement of the first edition, which received exceptionally good reviews when first published in 1979. It provides a survey of the topics which have been included under the name of hysteria and which are still of importance under the terms conversion and dissociation. Current concepts of repression, including the common modern problems of "multiple personality disorder" and "recovered memory" are discussed in detail. The whole range of hysterical phenomena is covered, from classical paralyses and blindness to questions about hysterical personality and epidemic hysteria.  
£30.00, 486pp., Hardback, 1995, ISBN 0 902241 88 5

Gaskell is the imprint of the Royal College of Psychiatrists. Gaskell books are available from good bookshops and from the Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146). The latest information on College publications is available on the INTERNET at: <http://www.demon.co.uk/rcpsych/>

